INCY vs SLS
Incyte vs SELLAS Life Sciences Group, Inc. — AI-powered side-by-side comparison
VS
SLS
SELLAS Life Sciences Group, Inc.
57
Watch
| Metric | INCY | SLS |
|---|
| AI Score |
72
|
57
|
| Price |
$121.08
|
$11.03
|
| P/E Ratio |
14.89×
|
-52.30×
|
| ROE |
24.9%
|
-37.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
0.0%
|
| Debt / Equity |
0.01×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
43.9
|
| Beta |
0.769
|
2.494
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus SLS.
INCY leads by 15 points.
INCY scores 72/100 (Buy) versus SLS at 57/100 (Watch).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
SLS Committee View
80% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -47.1% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical